These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17105860)

  • 1. Cyclic intravenous pamidronate treatment in children with nodulosis, arthropathy and osteolysis syndrome.
    Al-Mayouf SM; Madi SM; Bin-Abbas BS
    Ann Rheum Dis; 2006 Dec; 65(12):1672-3. PubMed ID: 17105860
    [No Abstract]   [Full Text] [Related]  

  • 2. Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome.
    Galli-Tsinopoulou A; Kyrgios I; Giza S; Giannopoulou EZ; Maggana I; Laliotis N
    Minerva Endocrinol; 2012 Sep; 37(3):283-9. PubMed ID: 22766895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome.
    Sakka S; Gafni RI; Davies JH; Clarke B; Tebben P; Samuels M; Saraff V; Klaushofer K; Fratzl-Zelman N; Roschger P; Rauch F; Högler W
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4163-4172. PubMed ID: 28938420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of zoledronic acid on acro-osteolysis and osteoporosis in a patient with Hajdu-Cheney syndrome.
    Hwang S; Shin DY; Moon SH; Lee EJ; Lim SK; Kim OH; Rhee Y
    Yonsei Med J; 2011 May; 52(3):543-6. PubMed ID: 21488202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions.
    Howe W; Davis E; Valentine J
    Dev Neurorehabil; 2010 Feb; 13(1):31-6. PubMed ID: 20067343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome: 2-year follow-up.
    McKiernan FE
    Osteoporos Int; 2008 Mar; 19(3):379-80. PubMed ID: 17874031
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome.
    McKiernan FE
    Osteoporos Int; 2007 Feb; 18(2):245-9. PubMed ID: 17103298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy.
    Bachrach SJ; Kecskemethy HH; Harcke HT; Lark RK; Miller F; Henderson RC
    J Clin Densitom; 2006; 9(2):167-74. PubMed ID: 16785077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Torg-Winchester syndrome: lack of efficacy of pamidronate therapy.
    Phadke SR; Ramirez M; DiFeo A; Martignetti JA; Girisha KM
    Clin Dysmorphol; 2007 Apr; 16(2):95-100. PubMed ID: 17351352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
    Land C; Rauch F; Montpetit K; Ruck-Gibis J; Glorieux FH
    J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
    Plotkin H; Coughlin S; Kreikemeier R; Heldt K; Bruzoni M; Lerner G
    Dev Med Child Neurol; 2006 Sep; 48(9):709-12. PubMed ID: 16904014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D; Coker M; Darcan S; Köse T; Kara S
    Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.